Filing summary
Registrant mismatch: The supplied filing is Priveterra Acquisition Corp.’s 2021 Form 10-K, not an AEON Biopharma, Inc. filing. AEON is mentioned as an entity with which director Vikram Malik has an affiliation. The summary below covers Priveterra.
Business context and reporting period
Priveterra was a blank-check company formed to pursue a business combination, with an intended focus on medical technology. This Form 10-K covers the fiscal year ended December 31, 2021; its prior-period comparison is only November 17, 2020 (inception) through December 31, 2020. At year-end, it had not begun operating or selected a target. It completed its IPO on February 11, 2021, issuing 27.6 million units at $10 each.
Financial results and liquidity
| Metric | FY 2021 / year-end |
|---|---|
| Revenue | None; the company had no operating revenue. |
| Net income | $8.20 million, including a $10.71 million unrealized gain from changes in warrant fair value and $79,687 of trust-account interest. Formation and operating costs were $1.94 million; warrant-related offering costs were $655,046. |
| Operating cash flow | $(1.49) million. |
| Cash and current assets | $497,412 in cash; $835,224 in current assets. |
| Current liabilities | $834,585, including $200,000 of franchise tax payable. |
| Trust investments | $276.08 million, invested in U.S. Treasury securities. |
| Total assets / total liabilities | $276.95 million / $17.88 million. Separately, $276 million of Class A shares was classified as redeemable temporary equity; stockholders’ deficit was $16.93 million. |
| Debt | No working-capital loan borrowings outstanding at year-end. A $100,000 sponsor loan had been converted into 66,667 warrants. |
Profit, margins and operating performance are not representative of an operating business: reported income was chiefly driven by a non-cash warrant revaluation. The prior period recorded a $3,588 net loss and is not a full-year comparable period.
Material changes, outlook and risks
- The company had until February 11, 2023—24 months after the IPO—to complete a business combination; otherwise, it generally had to cease operations, redeem public shares from the trust and liquidate. Public warrants could expire worthless if no combination was completed.
- Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern, citing limited operating liquidity, ongoing costs and the mandatory liquidation deadline. Management intended to complete a combination before the deadline.
- Management reported that working capital was $731,279 in its discussion, while the financial-statement note reports $200,639 excluding taxes payable; the balance-sheet figures imply $639 including the tax payable. The filing text does not reconcile these amounts.
- Disclosure controls and internal control over financial reporting were ineffective due to a material weakness in accounting for complex financial instruments. Management described remediation efforts; the auditor did not attest to internal controls because of the company’s emerging-growth-company status.
- Other material risks include claims against the trust account that could reduce public-share redemption proceeds, high redemption levels or unavailable financing preventing a transaction, conflicts of interest and competing obligations among management, and dilution from founder shares and warrants. COVID-19 effects and the financial impact of the Russia-Ukraine conflict were described as uncertain.
- No operating-business guidance or revenue outlook was provided. The company said it expected increased public-company and due-diligence costs and had no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer: this filing is for Priveterra Acquisition Corp. (PMGM), not AEON Biopharma.
- Reconcile the conflicting working-capital figures against the audited balance sheet and notes.
- Review the warrant valuation and the $10.71 million unrealized gain that drove reported net income.
- Check liquidity outside the trust, ongoing administrative costs, and the company’s ability to meet its business-combination deadline.
- Assess the material weakness, remediation progress, redemption mechanics, sponsor indemnity capacity and potential dilution.